Skip to main content

Intraocular Pressure

4
Pipeline Programs
7
Companies
9
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Alcon
AlconFORT WORTH, TX
1 program
1
Travoprost 0.004% + Brinzolamide 1.0%Phase 41 trial
Active Trials
NCT00758342Terminated37Est. Mar 2008
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
2 programs
1
1
BOL-303259-XPhase 21 trial
Latanoprostene bunodPhase 11 trial
Active Trials
NCT01895985Completed24Est. Oct 2013
NCT01223378Completed413Est. Jun 2012
Bausch + Lomb
Bausch + LombNJ - Bridgewater
1 program
1
BOL-303259-XPhase 2
Nidek
NidekJapan - Aichi
3 programs
NIDEK TONOREF IIIN/A1 trial
NIDEK TONOREF IIIN/A1 trial
Nidek Tonoref IIIN/A1 trial
Active Trials
NCT07152808Completed52Est. Jun 2023
NCT06363045Completed183Est. Dec 2024
NCT03441477Completed225Est. Jan 2019
Reichert
ReichertNY - Depew
1 program
IOP with Goldmann Applanation TonometerN/A1 trial
Active Trials
NCT04360369Completed61Est. Apr 2021
New World Medical
New World MedicalCA - Rancho Cucamonga
1 program
ab interno canaloplastyN/A1 trial
Active Trials
NCT04700189Completed42Est. Sep 2022
T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
nepafenacPHASE_41 trial
Active Trials
NCT01995890CompletedEst. Apr 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
T-Therapeuticsnepafenac
AlconTravoprost 0.004% + Brinzolamide 1.0%
Bausch HealthBOL-303259-X
Bausch HealthLatanoprostene bunod
NidekNIDEK TONOREF III
NidekNIDEK TONOREF III
New World Medicalab interno canaloplasty
ReichertIOP with Goldmann Applanation Tonometer
NidekNidek Tonoref III

Clinical Trials (9)

Total enrollment: 1,037 patients across 9 trials

NCT01995890T-Therapeuticsnepafenac

Effect of Nepafenac Eye Drops on Intraocular Pressure in Normal Eyes

Start: Dec 2012Est. completion: Apr 2013
Phase 4Completed
NCT00758342AlconTravoprost 0.004% + Brinzolamide 1.0%

Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)

Start: May 2006Est. completion: Mar 200837 patients
Phase 4Terminated
NCT01223378Bausch HealthBOL-303259-X

Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension

Start: Dec 2010Est. completion: Jun 2012413 patients
Phase 2Completed
NCT01895985Bausch HealthLatanoprostene bunod

Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers

Start: Jul 2013Est. completion: Oct 201324 patients
Phase 1Completed
NCT06363045NidekNIDEK TONOREF III

Comparative Study of the NIDEK TONOREF III with Predicate Devices

Start: Jun 2024Est. completion: Dec 2024183 patients
N/ACompleted
NCT07152808NidekNIDEK TONOREF III

Clinical Study for TONOREF III Tested to ANSI Z80.10-2014

Start: Sep 2022Est. completion: Jun 202352 patients
N/ACompleted
NCT04700189New World Medicalab interno canaloplasty

A FIH Trial of the STREAMLINE™ SURGICAL SYSTEM

Start: Dec 2020Est. completion: Sep 202242 patients
N/ACompleted
NCT04360369ReichertIOP with Goldmann Applanation Tonometer

Comparison of Intraocular Pressure Measurements Between Reichert Tono-Vera Tonometer and Goldmann Tonometry

Start: Oct 2020Est. completion: Apr 202161 patients
N/ACompleted
NCT03441477NidekNidek Tonoref III

Comparative Study of the NIDEK TONOREF III and the Haag-Streit Goldmann Manual Tonometer and Comparison of Pachymetry Values for NIDEK TONOREF III With the NIDEK CEM-530

Start: Dec 2017Est. completion: Jan 2019225 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.